These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1175 related articles for article (PubMed ID: 2254373)

  • 1. In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow.
    Fiebig HH; Berger DP; Köpping K; Ottenheijm HC; Zylicz Z
    J Cancer Res Clin Oncol; 1990; 116(6):550-6. PubMed ID: 2254373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development.
    Fiebig HH; Schmid JR; Bieser W; Henss H; Lohr GW
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):937-48. PubMed ID: 3665999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in mice.
    Hofs HP; Wagener DJ; De Vos D; Ottenheijm HC; Winkens HJ; Bovee PH; De Grip WJ
    Eur J Cancer; 1995; 31A(9):1526-30. PubMed ID: 7577083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas.
    Fodstad O; Aamdal S; Pihl A; Boyd MR
    Cancer Res; 1985 Apr; 45(4):1778-86. PubMed ID: 3978640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.
    Zylicz Z; Wagener DJ; van Rennes H; van der Kleijn E; Lelieveld P; van den Broek LA; Ottenheijm HC
    Invest New Drugs; 1988 Dec; 6(4):285-92. PubMed ID: 3229941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening.
    Berger DP; Henss H; Winterhalter BR; Fiebig HH
    Ann Oncol; 1990 Sep; 1(5):333-41. PubMed ID: 2261375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin.
    Kjønniksen I; Breistøl K; Fodstad O
    Cancer Res; 1992 Mar; 52(5):1347-51. PubMed ID: 1737396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.
    Pezzoni G; Grandi M; Biasoli G; Capolongo L; Ballinari D; Giuliani FC; Barbieri B; Pastori A; Pesenti E; Mongelli N
    Br J Cancer; 1991 Dec; 64(6):1047-50. PubMed ID: 1764367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
    Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical activity of hepsulfam and busulfan in solid human tumor xenografts and human bone marrow.
    Berger DP; Winterhalter BR; Dengler WA; Fiebig HH
    Anticancer Drugs; 1992 Oct; 3(5):531-9. PubMed ID: 1450448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
    Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
    Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide.
    Fairbairn LJ; Chinnasamy N; Lashford LS; Chinnasamy D; Rafferty JA
    Cancer Gene Ther; 2000 Feb; 7(2):233-9. PubMed ID: 10770631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
    Burres NS; Clement JJ
    Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent.
    Hickman JA; Stevens MF; Gibson NW; Langdon SP; Fizames C; Lavelle F; Atassi G; Lunt E; Tilson RM
    Cancer Res; 1985 Jul; 45(7):3008-13. PubMed ID: 4005840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
    Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
    Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity on murine tumors of a novel antitumor benzoylphenylurea derivative, HO-221.
    Nakajima T; Masuda H; Okamoto T; Watanabe M; Yokoyama K; Yamada N; Fujimoto S; Tsukagoshi S; Taguchi T
    Cancer Chemother Pharmacol; 1991; 28(5):351-6. PubMed ID: 1914078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
    Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
    Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups.
    Kraker AJ; Hoeschele JD; Elliott WL; Showalter HD; Sercel AD; Farrell NP
    J Med Chem; 1992 Nov; 35(24):4526-32. PubMed ID: 1335074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice.
    Cantrell JE; Green D; Schein PS
    Cancer Res; 1986 May; 46(5):2340-3. PubMed ID: 2938728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity.
    Slavik M; Blanc O; Davis J
    Invest New Drugs; 1983; 1(3):225-34. PubMed ID: 6678870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.